Skip to main content

Hsien-Yen
Chang
,
PhD

Associate Scientist

Contact Info

624 N. Broadway, Hampton House 682
Baltimore
Maryland
21205
US        

Research Interests

Risk Adjustment; Real-World Evidence; Drug Safety; Pharmacoepidemiology; Opioid abuse; Health services research
Experiences & Accomplishments
Education
PhD
Johns Hopkins Bloomberg School of Public Health
2008
MHS
Johns Hopkins Bloomberg School of Public Health
2006
MS
National Yang-Ming University
1997
MS
National Yang-Ming University
1997
BS
National Taiwan University
1995
Overview
Risk adjustment and its applications
Pharmacoepidemiology
Opioid abuse
Overuse measurements and their applications
Outcome evaluation and cost-effectiveness analysis
Honors & Awards
Phi Beta Kappa Honor Society, 2009-Present                     
Taiwan Merits Scholarships, 2005–2008                               
Rotary Foundation Academic-Year Ambassadorial Scholar, 2001–2002
Select Publications
Select publications from the last two years.
  • HY Chang, W Tang, E Hatef, C Kitchen, JP Weiner, H Kharrazi. Differential impact of mitigation policies and socioeconomic status on COVID-19 prevalence and social distancing in the United States. BMC public health. 2021: 21 (1), 1-10
  • HY Chang, E Hatef, X Ma, JP Weiner, H Kharrazi. Impact of area deprivation index on the performance of claims-based risk-adjustment models in predicting health care costs and utilization. Population Health Management. 2021: 24 (3), 403-411
  • HY Chang, YY Chou, W Tang, GM Chang, CF Hsieh, S Singh, YC Tung. Association of antidiabetic therapies with lower extremity amputation, mortality and healthcare cost from a nationwide retrospective cohort study in Taiwan. Scientific reports. 2021: 11 (1), 1-10
  • YC Tung, GH Li, HY Chang. External Validation of and Factors Associated with the Overuse Index: a Nationwide Population-Based Study from Taiwan. Journal of general internal medicine. 2021: 36 (2), 438-446
  • HY Chang, L Ferris, M Eisenberg, N Krawczyk, KE Schneider, K Lemke, et al. The impact of various risk assessment time frames on the performance of opioid overdose forecasting models. Medical care. 2020: 58 (11), 1013-1021